- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00712634
Cytomegalovirus Vaccine in Healthy Participants
A Phase I Dose Escalation Study of Lipopeptide Vaccines With Activity Against Human Cytomegalovirus
RATIONALE: Vaccines may help the body build an effective immune response against cytomegalovirus.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of cytomegalovirus vaccine in healthy participants.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- To establish whether 4 dose levels of the CMVpp65-A*0201 peptide vaccine are safe and well tolerated in cytomegalovirus (CMV)-seropositive participants.
- To determine whether the CMVpp65-A*0201 peptide vaccine, when given as a single injection followed by one booster injection at a safe and well-tolerated dose, is capable of stimulating a memory response in CMV-seropositive participants.
- To evaluate whether CMV-seronegative participants generate a de novo immune response against CMV after immunization with CMVpp65-A*0201 peptide vaccine given as a single injection followed by three booster injections.
- To determine the duration of immune enhancement of CMV-specific cytotoxic T-lymphocyte function as assessed for up to 12 months after primary or secondary immunization with the CMVpp65-A*0201 peptide vaccine.
OUTLINE: This is a dose-escalation study of CMVpp65-A*0201 peptide vaccine in cytomegalovirus (CMV)-seropositive participants. Once a safe dose is established, CMV-seronegative participants are accrued and immunized at that dose. Participants are stratified according to gender.
- CMV-seropositive participants: Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
- CMV-seronegative participants: Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
Participants undergo blood sample collection at baseline and periodically during study for immunologic laboratory studies. Participants also undergo skin biopsy at baseline. Laboratory studies include assessment of human cytotoxic T-lymphocyte activity and response by ^51chromium-release assay, limiting-dilution analysis, and T-cell proliferation assay; and CD4/CD8 phenotyping by FACScan® flow cytometry.
After completion of study therapy, participants are followed for 12 months.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010-3000
- City of Hope Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
- Healthy participant
- Cytomegalovirus seropositive or seronegative
- HLA-A*0201-positive
PATIENT CHARACTERISTICS:
- CBC within 1.5 times normal
- SMA-18 within 1.5 times normal
- Hepatitis B virus antigen seronegative
- Hepatitis C virus seronegative
- No diagnosis that is associated with immunodeficiency, including HIV infection
- No serious abnormalities by EKG (in participants ≥ 50 years of age)
- Not pregnant
PRIOR CONCURRENT THERAPY:
- More than 6 months since prior surgery
No concurrent daily medications for chronic or current illness, except for the following:
- Thyroid replacement therapy
- Estrogen replacement therapy
- Dietary vitamins and protein supplements
- Antihistamine medication
- Anticholesterol medication
- Cardiac and antihypertensive medication
- Any medication, as determined by the principal investigator, that is not known or likely to be immunosuppressive
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: CMV-seropositive participants
Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide.
Within each vaccine dose group, two participants are randomized to receive a placebo.
Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
|
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
|
Experimentell: CMV-seronegative participants
Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide.
Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity.
Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
|
Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
---|
Säkerhet och toxicitet
|
Immunologiskt svar
|
Duration of immunologic response
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Don Diamond, PhD, City of Hope Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CDR0000599675
- P01CA030206 (U.S.S. NIH-anslag/kontrakt)
- CHNMC-97092
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på CMVpp65-A*0201 peptide vaccine
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeHematopoetisk och lymfoid cellneoplasma | Myelofibros | Kronisk lymfatisk leukemi | Akut myeloid leukemi hos vuxna i remission | Myelodysplastiskt syndrom | Akut lymfoblastisk leukemi hos vuxna i remission | Myeloproliferativ neoplasma | Kronisk fas Kronisk myelogen leukemi, BCR-ABL1 positiv | Lymfoblast... och andra villkorFörenta staterna
-
Shiga UniversityTokyo UniversityAvslutad
-
Shiga UniversityTokyo UniversityAvslutadIcke-småcellig lungcancerJapan
-
Shiga UniversityHuman Genome Center, Institute of Medical Science, University of TokyoAvslutadIcke-småcellig lungcancerJapan
-
University of Lausanne HospitalsFond'action contre le cancer; Barletta Foundation; NCCR (National Center...Upphängd
-
COL George Peoples, MD, FACSAvslutadÄggstockscancer | Endometriecancer | Peritoneal cancer | Fallopian cancerFörenta staterna
-
Institute of Medical Biology, Chinese Academy of...Jiangsu Province Centers for Disease Control and PreventionAvslutad
-
Instituto Nacional de Salud Publica, MexicoLaboratorios de Biologicos y Reactivos de México, S.A. de C.V.Indragen
-
University of RochesterNational Institutes of Health (NIH)Indragen2009 H1N1 influensaFörenta staterna
-
National Institute of Allergy and Infectious Diseases...AvslutadInfluensaFörenta staterna